TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27537995

Group type: EXPERIMENTAL
Intervention: Cal/BD aerosol foam
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Cal/BD ointment
Number of subjects: 1104

Group type: COMPARATOR
Intervention: BD aerosol foam
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Cal aerosol foam
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Aerosol foam vehicle
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Ointment vehicle
Number of subjects: 1104
Study: 24595800

Group type: EXPERIMENTAL
Intervention: MarginProbe device
Number of subjects: 596

Group type: COMPARATOR
Intervention: Control (standard intraoperative methods for margin assessment)
Number of subjects: 596
Study: 22791622

Group type: EXPERIMENTAL
Intervention: Wingate test at 07:00-h
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Wingate test at 17:00-h
Number of subjects: 15
Study: 20517667

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Prebiotics and heat-deactivated probiotics
Number of subjects: 68

Group type: COMPARATOR
Intervention: Mechanical bowel cleaning
Number of subjects: 68
Study: 18773730

Group type: EXPERIMENTAL
Intervention: Assessments of body shape attractiveness across seasons
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Assessments of breast attractiveness across seasons
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Assessments of face attractiveness across seasons
Number of subjects: 114
Study: 15749734

Group type: EXPERIMENTAL
Intervention: A-line AEP Monitor at AAI 10
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: End-expiratory sevoflurane concentration
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: A-line AEP Monitor
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: AAI for 90% probability of acceptable intubation conditions
Number of subjects: 108
Study: 14508821

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (NSABP B-04)
Number of subjects: 3515

Group type: COMPARATOR
Intervention: No radiotherapy (NSABP B-04)
Number of subjects: 3515

Group type: EXPERIMENTAL
Intervention: Postlumpectomy breast irradiation (NSABP B-06)
Number of subjects: 3515

Group type: COMPARATOR
Intervention: Total mastectomy or lumpectomy without radiotherapy (NSABP B-06)
Number of subjects: 3515
Study: 11304721

Group type: EXPERIMENTAL
Intervention: 220 mg of naproxen sodium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50 mg of diphenhydramine hydrochloride
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 220 mg of naproxen sodium with 50 mg of diphenhydramine hydrochloride
Number of subjects: 30
Study: 8625666

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1430394

Group type: EXPERIMENTAL
Intervention: 0.5 ml of MPI 5003
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.25 ml of MPI 5003
Number of subjects: 20
Study: 6230059

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 23
Study: 3511162

Group type: EXPERIMENTAL
Intervention: Silastic coated incus
Number of subjects: 54

Group type: COMPARATOR
Intervention: Uncoated incus
Number of subjects: 54
Study: 30175493

Group type: EXPERIMENTAL
Intervention: Carotid IMT
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aortic IMT
Number of subjects: 90
Study: 26984210

Group type: EXPERIMENTAL
Intervention: PF-06439535
Number of subjects: 102

Group type: COMPARATOR
Intervention: bevacizumab-EU
Number of subjects: 102

Group type: COMPARATOR
Intervention: bevacizumab-US
Number of subjects: 102
Study: 25490367

Group type: EXPERIMENTAL
Intervention: Endoscopic vein exposure (EVE)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Open method of vein exposure (OVE)
Number of subjects: 228
Study: 22104363

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 20044537

Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 305
Study: 18711764

Group type: EXPERIMENTAL
Intervention: Mitomycin (MMC) 8 mg/m(2) on day 1 and cisplatin (DDP) 25 mg/m(2) on days 1 to 3 with Kanglaite (KLT) 100 ml intravenously per day on days 1 to 14 every 3 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mitomycin (MMC) 8 mg/m(2) on day 1 and cisplatin (DDP) 25 mg/m(2) on days 1 to 3 without Kanglaite (KLT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with complete or partial responses
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with stable or progressive disease (SD or PD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with clinical benefit from chemotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with stable disease of no more than 6 months or progressive disease
Number of subjects: 60
Study: 15918104

Group type: EXPERIMENTAL
Intervention: Dual RAAS blockade (angiotensin II receptor blocker + ACE inhibitor)
Number of subjects: 51
Study: 12971702

Group type: EXPERIMENTAL
Intervention: Enhanced upper limb rehabilitation provided jointly by a physiotherapist and occupational therapist, commencing within 10 days of stroke, available up to 30 minutes/day, five days/week for six weeks.
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group received stroke unit care.
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Enhanced upper limb therapy (intervention group)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group therapy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Total amount of inpatient physiotherapy and occupational therapy received by the intervention group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Service costs
Number of subjects: 123
Study: 11009238

Group type: EXPERIMENTAL
Intervention: Plain mixture LBH (2.5 mL lidocaine 2%, 2.5 mL bupivacaine 0.5%, 5 IU/mL hyaluronidase, and 0.125 mL isotonic saline)
Number of subjects: 29

Group type: COMPARATOR
Intervention: pH-adjusted mixture LBH-PH (2.5 mL lidocaine 2%, 2.5 mL bupivacaine 0.5%, 5 IU/mL hyaluronidase, and 0.125 mL sodium bicarbonate 8.4%)
Number of subjects: 29
Study: 8769362

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) administration (0.1 IU/kg.d)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: T3 administration (40 micrograms on even dates or 20 micrograms on uneven dates)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined GH and T3 administration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1532948

Group type: EXPERIMENTAL
Intervention: 40% urea ointment with 1% bifonazole (group A)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 40% urea ointment with 1% bifonazole and oral griseofulvin 500 mg/day (group B)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Oral griseofulvin alone
Number of subjects: 22
Study: 3907295

Group type: EXPERIMENTAL
Intervention: lipid-lowering diet with cholestyramine, nicotinic acid or clofibrate
Number of subjects: 25

Group type: COMPARATOR
Intervention: usual-care
Number of subjects: 25
Study: 30794232

Group type: EXPERIMENTAL
Intervention: Self-reported marijuana use after legalization
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Recreational use reported after legalization
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Medicinal use reported after legalization
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: No reason for use reported after legalization
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Both recreational and medicinal use reported after legalization
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Factors associated with marijuana use
Number of subjects: 1000
Study: 29772982

Group type: EXPERIMENTAL
Intervention: Metal needles
Number of subjects: 33

Group type: COMPARATOR
Intervention: Plastic cannulae
Number of subjects: 33
Study: 27089362

Group type: COMPARATOR
Intervention: Upright seated position (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: -20° head-down tilted position (inversion)
Number of subjects: 8
Study: 25523961

Group type: EXPERIMENTAL
Intervention: Subgingival mechanical therapy with azithromycin
Number of subjects: 105

Group type: COMPARATOR
Intervention: Subgingival mechanical therapy with placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Supragingival prophylaxis with azithromycin
Number of subjects: 105
Study: 22297666

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (target range 80–110 mg/dl)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conservative glycemic control (target range 140–180 mg/dl)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study: 20473192

Group type: EXPERIMENTAL
Intervention: Randomized studies
Number of subjects: 1851

Group type: EXPERIMENTAL
Intervention: Ceramic-on-polyethylene hip from one study
Number of subjects: 1851
Study: 17700444

Group type: EXPERIMENTAL
Intervention: Modified double‐door laminoplasty (Lamino group; n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Skip laminectomy (Skip group; n = 20)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Modified double‐door laminoplasty (Lamino group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Skip laminectomy (Skip group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 15977742

Group type: EXPERIMENTAL
Intervention: Adaptive model initialization and deformation for automatic segmentation of T1-weighted brain MRI data
Number of subjects: 28
Study: 12079445

Group type: EXPERIMENTAL
Intervention: Motivational intervention to increase mammography rates
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 196
Study: 10811588

Group type: EXPERIMENTAL
Intervention: Thrombolysis with standard aspirin and beta-blockade
Number of subjects: 37069

Group type: EXPERIMENTAL
Intervention: Nomogram based on Cox model
Number of subjects: 37069

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 37069

Group type: EXPERIMENTAL
Intervention: Demographic and clinical factors
Number of subjects: 37069

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 37069
Study: 8979037

Group type: EXPERIMENTAL
Intervention: Conventional hearing aid
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Assistive listening device
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of both systems
Number of subjects: 180

Group type: COMPARATOR
Intervention: No amplification condition
Number of subjects: 180
Study: 1599892

Group type: EXPERIMENTAL
Intervention: 0.2 mg of morphine in 0.2 ml volume mixed with 0.75% bupivacaine and 0.2 ml 1:1000 epinephrine (Group 1, n = 40)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Saline in 0.2 ml volume mixed with 0.75% bupivacaine and 0.2 ml 1:1000 epinephrine (Group 2, n = 42)
Number of subjects: 82
Study: 3881447

Group type: EXPERIMENTAL
Intervention: Open reduction with rigid internal fixation
Number of subjects: 138

Group type: COMPARATOR
Intervention: Closed treatment in a plaster cast
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Open reduction with internal fixation of only the medial malleolus
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Open reduction with rigid internal fixation according to ASIF techniques
Number of subjects: 138
Study: 31085933

Group type: EXPERIMENTAL
Intervention: Air tamponade
Number of subjects: 34

Group type: COMPARATOR
Intervention: Balanced salt solution
Number of subjects: 34
Study: 29336101

Group type: EXPERIMENTAL
Intervention: Cidofovir
Number of subjects: 180

Group type: COMPARATOR
Intervention: Imiquimod
Number of subjects: 180
Study: 28214082

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (6mg/h)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: All groups (RIPC, nicorandil, control)
Number of subjects: 391
Study: 26177235

Group type: COMPARATOR
Intervention: Real rTMS (n = 10), 1200 pulses at 1 Hz for 20 min, five daily sessions over the contralesional motor cortex.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation (n = 10), same duration and frequency as rTMS but without active stimulation.
Number of subjects: 20
Study: 23405947

Group type: EXPERIMENTAL
Intervention: Weight loss during index admission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increase in cardiac index/cardiac output
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acute heart failure (ischemic or nonischemic)
Number of subjects: 0
Study: 21666990

Group type: EXPERIMENTAL
Intervention: hexameter recitation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: alliteration recitation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: prose verse recitation
Number of subjects: 17
Study: 18645140

Group type: EXPERIMENTAL
Intervention: sorafenib (n = 43)
Number of subjects: 85

Group type: COMPARATOR
Intervention: placebo (n = 42)
Number of subjects: 85
Study: 17305206

Group type: EXPERIMENTAL
Intervention: Justice-based service recovery strategies (interactional justice, distributive justice, and combination)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No service failure (control condition)
Number of subjects: 0
Study: 14597909

Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated n-3 fatty acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA; 18:3 n-3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 10969367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microgram.kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil 2 micrograms.kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil 4 micrograms.kg‐1
Number of subjects: 40
Study: 9286850

Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Mibefradil 25 mg
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Mibefradil (all doses)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Mibefradil (50 mg and 100 mg)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 865
Study: 8358913

Group type: EXPERIMENTAL
Intervention: Ender nails
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Sliding screw plate (SSP)
Number of subjects: 92
Study: 3534592

Group type: EXPERIMENTAL
Intervention: CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone) for 1 year
Number of subjects: 366

Group type: COMPARATOR
Intervention: L-PAM (melphalan) for 2 years
Number of subjects: 366
Study: 29198406

Group type: EXPERIMENTAL
Intervention: Aliskiren (150-300mg orally per day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Negative control (no aliskiren treatment)
Number of subjects: 28
Study: 28664839

Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 µg/day for 24 weeks)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 25070746

Group type: EXPERIMENTAL
Intervention: Peppermint aroma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lavender aroma
Number of subjects: 0
Study: 23511346

Group type: EXPERIMENTAL
Intervention: Computerized math training for 5 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Computerized math training
Number of subjects: 58
Study: 20810675

Group type: EXPERIMENTAL
Intervention: ASV with protocolized de-escalation (ASV-DE)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard ASV
Number of subjects: 126
Study: 18413499

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control subjects (no CPAP therapy)
Number of subjects: 32
Study: 16763008

Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 983

Group type: COMPARATOR
Intervention: COC
Number of subjects: 983
Study: 14634567

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted magnetic resonance imaging
Number of subjects: 17
Study: 10762497

Group type: EXPERIMENTAL
Intervention: Remacemide 600 mg daily for 5 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Remacemide 150 mg or 300 mg daily for 5 weeks
Number of subjects: 200
Study: 8717532

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measurements
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lean body mass measurements
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Fat mass measurements
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: BMD comparison between fractured and uninjured hip
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Postoperative mortality and complications prediction
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comparison of survivors and non-survivors
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comparison of healed fractures and complications
Number of subjects: 102
Study: 7848615

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 828

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Lisinopril (Women)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Lisinopril (Men)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Nifedipine (Women)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Nifedipine (Men)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 828
Study: 2904203

Group type: EXPERIMENTAL
Intervention: topical timolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: betaxolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: topical timolol and betaxolol
Number of subjects: 12
Study: 31082356

Group type: EXPERIMENTAL
Intervention: Low-risk group (n=317)
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Medium-risk group (n=317)
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: High-risk group (n=317)
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Validation cohort (n=316) Low-risk group
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Validation cohort (n=316) Medium-risk group
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Validation cohort (n=316) High-risk group
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: UNOS dataset (n=9920) Low-risk group
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: UNOS dataset (n=9920) Medium-risk group
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: UNOS dataset (n=9920) High-risk group
Number of subjects: 633
Study: 28470159

Group type: EXPERIMENTAL
Intervention: Children's sex education program for parents (5-week, 5-session program)
Number of subjects: 58
Study: 25853697

Group type: EXPERIMENTAL
Intervention: Endobronchial Coils treatment
Number of subjects: 45
Study: 23552126

Group type: EXPERIMENTAL
Intervention: Doctor blood pressure measurement
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nurse blood pressure measurement
Number of subjects: 19
Study: 21225292

Group type: EXPERIMENTAL
Intervention: 5 mg 0.5% ropivacaine plus 25 μg fentanyl (group RF)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3.75 mg 0.75% levobupivacaine plus 25 μg fentanyl (group LF)
Number of subjects: 50
Study: 19555390

Group type: EXPERIMENTAL
Intervention: KM3934 (mouse-human chimeric IgG1)
Number of subjects: 0
Study: 17724209

Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 15
Study: 15454352

Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 11474160

Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 57

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 57
Study: 9709140

Group type: EXPERIMENTAL
Intervention: Vecuronium bromide 0.25 ml (0.5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline 0.25 ml
Number of subjects: 60
Study: 8574271

Group type: EXPERIMENTAL
Intervention: Oral oxandrolone (ASOX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Testosterone enanthate (TE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Parenteral nandrolone decanoate (ASND)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Weight loss alone (PL)
Number of subjects: 30
Study: 2159509

Group type: EXPERIMENTAL
Intervention: High-sodium diet (200 mmol/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-sodium diet (20 mmol/day)
Number of subjects: 18
Study: 380595

Group type: EXPERIMENTAL
Intervention: Chloramphenicol plus oxyphenbutazone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Chloramphenicol alone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Ampicillin plus oxyphenbutazone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 94
Study: 31272550

Group type: EXPERIMENTAL
Intervention: Rituximab 1,000 mg intravenous on days 0 and 12 post-transplant
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 163
Study: 28948482

Group type: EXPERIMENTAL
Intervention: Single 90-mg dose of hydrocodone ER under fed conditions
Number of subjects: 83

Group type: COMPARATOR
Intervention: Single 90-mg dose of hydrocodone ER under fasted conditions
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Multiple doses of hydrocodone ER (45 mg twice daily on days 2-3, 60 mg twice daily on days 4-5, 90 mg twice daily on days 6-10, and 90 mg once in the morning on day 11) under fed conditions
Number of subjects: 83

Group type: COMPARATOR
Intervention: Multiple doses of hydrocodone ER under fasted conditions
Number of subjects: 83
Study: 26149601

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride (BH) spray
Number of subjects: 92
Study: 24579355

Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES) combined with general anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received simple general anesthesia
Number of subjects: 60